Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
Cantor Fitzgerald
US Department of Justice

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,345,692

« Back to Dashboard

Title:Pharmaceutical formulations: salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxy-methyl]-8-phenyl-1,7-diaza-s- piro[4.5]decan-2-one and treatment methods using the same
Abstract: Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.
Inventor(s): Qiu; Zhihui (Bridgewater, NJ), Reyderman; Larisa (Watchung, NJ)
Assignee: OPKO Health, Inc. (Miami, FL)
Filing Date:Mar 19, 2013
Application Number:13/847,242
Claims:1. A method of treating nausea and/or emesis in a mammal comprising administering to the mammal a pharmaceutical formulation comprising a crystalline tosylate salt of (5S,8S)-8-[{(1R)-1-(3,5-bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one, and a pharmaceutically acceptable excipient, and wherein said nausea and/or emesis arises from chemotherapy, radiation therapy, motion sickness, morning sickness, or inner ear disturbances and infections, or wherein said nausea and/or emesis arises during a post-operative recovery period.

2. The method according to claim 1 wherein the pharmaceutically acceptable excipient is selected from at least one of the group consisting of lactose, microcrystalline cellulose, croscarmellose sodium, pregelantinized starch, and magnesium stearate.

3. The method of claim 1 wherein the formulation is a granular formulation.

4. The method of claim 1 wherein the amount of active ingredient ranges from 5-200 mg per dosage form.

5. The method of claim 1 wherein the dosage form contains 200 mg of the crystalline tosylate salt (5S,8S)-8-[{(1R)-I-(3,5-Bis-(trifluoromethyl)pheny]-ethoxy}-methyl]-8-phe- nyl-1,7-diazaspiro[4.5]decan-2-one.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Argus Health
Chinese Patent Office
Harvard Business School
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.